REFERENCES
1. Mavrommati I, Johnson F, Echeverria GV, Natrajan R. Subclonal heterogeneity and evolution in breast cancer. NPJ Breast Cancer 2021;7:155.
2. Yang R, Li Y, Wang H, Qin T, Yin X, Ma X. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed 2022;3:8.
3. Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular subtypes of breast cancer. Am J Physiol Cell Physiol 2021;321:C343-54.
4. Blucher AS, Mills GB, Tsang YH. Precision oncology for breast cancer through clinical trials. Clin Exp Metastasis 2022;39:71-8.
5. Zambelli A, Sgarra R, De Sanctis R, Agostinetto E, Santoro A, Manfioletti G. Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. Expert Opin Ther Targets 2022;26:557-73.
6. Pasha N, Turner NC. Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. Nat Cancer 2021;2:680-92.
7. Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci 2022;23:1665.
8. Li A, Keck JM, Parmar S, et al. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precis Oncol 2021;5:28.
9. Zong Y, Pegram M. Research advances and new challenges in overcoming triple-negative breast cancer. Cancer Drug Resist 2021;4:517-42.
10. Bishayee A, Block K. A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead. Semin Cancer Biol 2015;35 Suppl:S1-4.
12. Ferguson LR, Chen H, Collins AR, et al. Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol 2015;35 Suppl:S5-S24.
13. Feitelson MA, Arzumanyan A, Kulathinal RJ, et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol 2015;35 Suppl:S25-54.
14. Amin ARMR, Karpowicz PA, Carey TE, et al. Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol 2015;35 Suppl:S55-77.
15. Mohammad RM, Muqbil I, Lowe L, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol 2015;35 Suppl:S78-S103.
16. Yaswen P, MacKenzie KL, Keith WN, et al. Therapeutic targeting of replicative immortality. Semin Cancer Biol 2015;35 Suppl:S104-28.
17. Hirschey MD, DeBerardinis RJ, Diehl AME, et al. Target Validation Team. Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol 2015;35 Suppl:S129-50.
18. Samadi AK, Bilsland A, Georgakilas AG, et al. A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol 2015;35 Suppl:S151-84.
19. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015;35 Suppl:S185-98.
20. Casey SC, Amedei A, Aquilano K, et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol 2015;35 Suppl:S199-223.
21. Wang Z, Dabrosin C, Yin X, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 2015;35 Suppl:S224-43.
22. Jiang WG, Sanders AJ, Katoh M, et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol 2015;35 Suppl:S244-75.
23. Block KI, Gyllenhaal C, Lowe L, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 2015;35 Suppl:S276-304.
24. Liao CL, Peng SF, Chen JC, et al. Allyl isothiocyanate induces DNA damage and impairs DNA repair in human breast cancer MCF-7 cells. Anticancer Res 2021;41:4343-51.
25. Geng A, Xu S, Yao Y, et al. Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells. Cell Cycle 2022;21:379-91.
26. Sameni S, Hande MP. Plumbagin triggers DNA damage response, telomere dysfunction and genome instability of human breast cancer cells. Biomed Pharmacother 2016;82:256-68.
27. Kowsari H, Davoodvandi A, Dashti F, et al. Resveratrol in cancer treatment with a focus on breast cancer. Curr Mol Pharmacol 2022; doi: 10.2174/1874467215666220616145216.
28. Yuri T, Danbara N, Tsujita-kyutoku M, et al. Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 2004;84:251-60.
29. Guan X, Guan Y. Artemisinin induces selective and potent anticancer effects in drug resistant breast cancer cells by inducing cellular apoptosis and autophagy and G2/M cell cycle arrest. J BUON 2020;25:1330-6.
30. Mahmoud MA, Okda TM, Omran GA, Abd-Alhaseeb MM. Rosmarinic acid suppresses inflammation, angiogenesis, and improves paclitaxel induced apoptosis in a breast cancer model via NF3 κB-p53-caspase-3 pathways modulation. J Appl Biomed 2021;19:202-9.
31. Yao M, Fan X, Yuan B, et al. Berberine inhibits NLRP3 Inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell. BMC Complement Altern Med 2019;19:216.
32. Song X, Zhang M, Dai E, Luo Y. Molecular targets of curcumin in breast cancer (Review). Mol Med Rep 2019;19:23-9.
33. Banerjee N, Talcott S, Safe S, Mertens-Talcott SU. Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation. Breast Cancer Res Treat 2012;136:21-34.
34. Mehta R, Katta H, Alimirah F, et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One 2013;8:e65113.
35. Wu HT, Lin J, Liu YE, et al. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. Phytomedicine 2021;81:153437.
36. Kim SH, Hahm ER, Arlotti JA, et al. Withaferin a inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer Res Treat 2016;157:41-54.
37. Hahm ER, Kim SH, Singh KB, Singh K, Singh SV. A comprehensive review and perspective on anticancer mechanisms of withaferin a in breast cancer. Cancer Prev Res (Phila) 2020;13:721-34.
38. Cao X, Li Y, Wang Y, et al. Curcumin suppresses tumorigenesis by ferroptosis in breast cancer. PLoS One 2022;17:e0261370.
39. Huang CY, Han Z, Li X, Xie HH, Zhu SS. Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer. Oncol Lett 2017;14:3623-7.
40. Messeha SS, Zarmouh NO, Mendonca P, Alwagdani H, Cotton C, Soliman KFA. Effects of gossypol on apoptosis-related gene expression in racially distinct triple-negative breast cancer cells. Oncol Rep 2019;42:467-78.
41. Gao H, Zhang Y, Dong L, et al. Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells. Exp Ther Med 2018;15:3413-9.
43. Khalki L, Maire V, Dubois T, Zyad A. Berberine impairs the survival of triple negative breast cancer cells: cellular and molecular analyses. Molecules 2020;25:506.
44. Zhu Y, Xie N, Chai Y, et al. Apoptosis induction, a sharp edge of berberine to exert anti-cancer effects, focus on breast, lung, and liver cancer. Front Pharmacol 2022;13:803717.
45. Ávila-Gálvez MÁ, González-Sarrías A, Martínez-Díaz F, et al. Disposition of dietary polyphenols in breast cancer patients’ tumors, and their associated anticancer activity: the particular case of curcumin. Mol Nutr Food Res 2021;65:e2100163.
46. Nasiri M, Zarghami N, Koshki KN, et al. Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev 2013;14:3449-53.
47. Lee YH, Yuk HJ, Park KH, Bae YS. Coumestrol induces senescence through protein kinase CKII inhibition-mediated reactive oxygen species production in human breast cancer and colon cancer cells. Food Chem 2013;141:381-8.
48. Lewinska A, Adamczyk-Grochala J, Kwasniewicz E, Deregowska A, Wnuk M. Diosmin-induced senescence, apoptosis and autophagy in breast cancer cells of different p53 status and ERK activity. Toxicol Lett 2017;265:117-30.
49. Gomez LS, Zancan P, Marcondes MC, et al. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 2013;95:1336-43.
50. Shao S, Zhao L, An G, et al. Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer. FASEB J 2020;34:10860-70.
51. Chen Y, Zhang J, Zhang M, et al. Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α. Clin Transl Med 2021;11:e577.
52. Chai XX, Le YF, Wang JC, et al. Carpesium abrotanoides (L.) root as a potential source of natural anticancer compounds: targeting glucose metabolism and PKM2/HIF-1α axis of breast cancer cells. J Food Sci 2019;84:3825-32.
53. Li W, Song K, Wang S, et al. Anti-tumor potential of astragalus polysaccharides on breast cancer cell line mediated by macrophage activation. Mater Sci Eng C Mater Biol Appl 2019;98:685-95.
54. Jeong MH, Lee CM, Lee SW, et al. Cordycepin-enriched Cordyceps militaris induces immunomodulation and tumor growth delay in mouse-derived breast cancer. Oncol Rep 2013;30:1996-2002.
55. Pan J, Shen J, Si W, et al. Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway. Oncotarget 2017;8:65743-58.
56. Bimonte S, Barbieri A, Palma G, et al. Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer. Biomed Res Int 2015;2015:878134.
57. Gu JW, Makey KL, Tucker KB, et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression. Vasc Cell 2013;5:9.
58. Karadas AK, Dilmac S, Aytac G, Tanriover G. Melatonin decreases metastasis, primary tumor growth and angiogenesis in a mice model of breast cancer. Hum Exp Toxicol 2021;40:1545-57.
59. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res 2013;54:373-80.
60. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 2006;231:113-22.
61. Wei Z, Shan Y, Tao L, et al. Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and decreases breast cancer metastasis. Mol Carcinog 2017;56:2317-31.
62. Sun Y, Zhou QM, Lu YY, et al. Resveratrol inhibits the migration and metastasis of MDA-MB-231 human breast cancer by reversing TGF-β1-induced epithelial-mesenchymal transition. Molecules 2019;24:1131.
63. Zhou J, Zhu YF, Chen XY, et al. Black rice-derived anthocyanins inhibit HER-2-positive breast cancer epithelial-mesenchymal transition-mediated metastasis in vitro by suppressing FAK signaling. Int J Mol Med 2017;40:1649-56.
64. Liu C, Qi M, Li L, Yuan Y, Wu X, Fu J. Natural cordycepin induces apoptosis and suppresses metastasis in breast cancer cells by inhibiting the Hedgehog pathway. Food Funct 2020;11:2107-16.
65. Cheuk IW, Chen J, Siu M, et al. Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast cancer. Clin Transl Oncol 2022;24:854-63.
66. Li Q, Xia J, Yao Y, Gong DW, Shi H, Zhou Q. Sulforaphane inhibits mammary adipogenesis by targeting adipose mesenchymal stem cells. Breast Cancer Res Treat 2013;141:317-24.
67. Rong Y, Huang L, Yi K, et al. Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells. Cancer Lett 2020;493:189-96.
68. Farghadani R, Naidu R. Curcumin as an enhancer of therapeutic efficiency of chemotherapy drugs in breast cancer. Int J Mol Sci 2022;23:2144.
69. Ávila-Gálvez MÁ, Giménez-Bastida JA, Espín JC, González-Sarrías A. Dietary phenolics against breast cancer. A critical evidence-based review and future perspectives. Int J Mol Sci 2020;21:5718.
70. Monisha J, Padmavathi G, Roy NK, et al. NF-κB blockers gifted by mother nature: prospectives in cancer cell chemosensitization. Curr Pharm Des 2016;22:4173-200.
71. Khatoon E, Banik K, Harsha C, et al. Phytochemicals in cancer cell chemosensitization: current knowledge and future perspectives. Semin Cancer Biol 2022;80:306-39.
72. Ahire V, Kumar A, Mishra KP, Kulkarni G. Ellagic acid enhances apoptotic sensitivity of breast cancer cells to γ-radiation. Nutr Cancer 2017;69:904-10.
73. Wang W, Lv M, Huangfu C, Wang F, Zhang J. 3,3’-Diindolylmethane: a promising sensitizer of γ-irradiation. Biomed Res Int 2015;2015:465105.
74. Wang J, Liu Q, Yang Q. Radiosensitization effects of berberine on human breast cancer cells. Int J Mol Med 2012;30:1166-72.
75. Al-Abbasi FA, Alghamdi EA, Baghdadi MA, et al. Gingerol synergizes the cytotoxic effects of doxorubicin against liver cancer cells and protects from its vascular toxicity. Molecules 2016;21:886.
76. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919-30.
77. Angelis ML, Francescangeli F, Zeuner A. Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities. Cancers (Basel) 2019;11:1569.
78. Ke DYJ, El-Sahli S, Wang L. The potential of natural products in the treatment of triple-negative breast cancer. Curr Cancer Drug Targets 2022;22:388-403.
79. Retsky M, Demicheli R, Hrushesky WJ, et al. Promising development from translational or perhaps anti-translational research in breast cancer. Clin Transl Med 2012;1:17.
80. Retsky M, Demicheli R, Hrushesky W, et al. Breast cancer and the black swan. Ecancermedicalscience 2020;14:1050.
81. Deng X, Nakamura Y. Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy. Trends Pharmacol Sci 2017;38:15-24.
82. Paller CJ, Denmeade SR, Carducci MA. Challenges of conducting clinical trials of natural products to combat cancer. Clin Adv Hematol Oncol 2016;14:447-55.
84. Le TQ, Smith L, Harnett J. A systematic review - biologically-based complementary medicine use by people living with cancer - is a more clearly defined role for the pharmacist required? Res Social Adm Pharm 2017;13:1037-44.
85. Yen C, Zhao F, Yu Z, Zhu X, Li CG. Interactions between natural products and tamoxifen in breast cancer: a comprehensive literature review. Front Pharmacol 2022;13:847113.
86. Lopez G, McQuade J, Cohen L, et al. Integrative oncology physician consultations at a comprehensive cancer center: analysis of demographic, clinical and patient reported outcomes. J Cancer 2017;8:395-402.
87. Standish LJ, Dowd F, Sweet E, et al. Breast cancer integrative oncology care and its costs. Integr Cancer Ther 2017;16:85-95.
